[go: up one dir, main page]

WO1998006861A3 - Delivery of tolerogenic antigens via edible plants or plant-derived products - Google Patents

Delivery of tolerogenic antigens via edible plants or plant-derived products Download PDF

Info

Publication number
WO1998006861A3
WO1998006861A3 PCT/US1997/013634 US9713634W WO9806861A3 WO 1998006861 A3 WO1998006861 A3 WO 1998006861A3 US 9713634 W US9713634 W US 9713634W WO 9806861 A3 WO9806861 A3 WO 9806861A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
plant
derived products
edible plants
antigens via
Prior art date
Application number
PCT/US1997/013634
Other languages
French (fr)
Other versions
WO1998006861A2 (en
Inventor
Lisa M Welter
Original Assignee
Agrivax Inc
Lisa M Welter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agrivax Inc, Lisa M Welter filed Critical Agrivax Inc
Priority to AU38254/97A priority Critical patent/AU3825497A/en
Priority to CA002263730A priority patent/CA2263730A1/en
Priority to EP97935275A priority patent/EP0939826A2/en
Publication of WO1998006861A2 publication Critical patent/WO1998006861A2/en
Publication of WO1998006861A3 publication Critical patent/WO1998006861A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C12N15/8207—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Insects & Arthropods (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)

Abstract

Autoantigens and allergens can be expressed in transgenic plants, and the plants, or products derived therefrom, used as foods or beverages to prevent or treat autoimmune diseases or allergic reactions.
PCT/US1997/013634 1996-08-15 1997-08-05 Delivery of tolerogenic antigens via edible plants or plant-derived products WO1998006861A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU38254/97A AU3825497A (en) 1996-08-15 1997-08-05 Delivery of tolerogenic antigens via edible plants or plant-derived products
CA002263730A CA2263730A1 (en) 1996-08-15 1997-08-05 Delivery of tolerogenic antigens via edible plants or plant-derived products
EP97935275A EP0939826A2 (en) 1996-08-15 1997-08-05 Delivery of tolerogenic antigens via edible plants or plant-derived products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2397396P 1996-08-15 1996-08-15
US60/023,973 1996-08-15

Publications (2)

Publication Number Publication Date
WO1998006861A2 WO1998006861A2 (en) 1998-02-19
WO1998006861A3 true WO1998006861A3 (en) 1998-05-14

Family

ID=21818189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013634 WO1998006861A2 (en) 1996-08-15 1997-08-05 Delivery of tolerogenic antigens via edible plants or plant-derived products

Country Status (4)

Country Link
EP (1) EP0939826A2 (en)
AU (1) AU3825497A (en)
CA (1) CA2263730A1 (en)
WO (1) WO1998006861A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757874B1 (en) * 1996-12-17 2003-04-25 Biocem RECOMBINANT COLLAGENS AND DERIVED PROTEINS PRODUCED BY PLANTS, THEIR METHODS OF OBTAINING AND THEIR USES
FR2759857B1 (en) * 1997-02-27 1999-04-30 Biocem NEW USES OF MALE STERILITY IN PLANTS
DE19834909A1 (en) * 1998-08-03 2000-02-17 Mpb Cologne Gmbh Molecular Pla Fiber proteins and their production
KR20010085901A (en) * 1998-10-07 2001-09-07 릴리 엠 씨즐러 스피허, 아네뜨 워너 Therapeutically active proteins in plants
US20020009452A1 (en) * 1999-02-10 2002-01-24 Michael Caplan Method for altering undesirable immune responses to polypeptides
WO2001077353A2 (en) * 2000-04-05 2001-10-18 Syngenta Participations Ag Expression of pollen allergens in plastids
FR2841906B1 (en) * 2002-07-05 2006-08-18 Stallergenes Sa NUCLEIC ACID MOLECULE ENCODING AN ALLERGENE PREPROPROTEIN OF A MITER OF THE GENUS DERMATOPHAGOIDES OR EUROGLYPHUS AND USE THEREOF FOR THE PRODUCTION OF SAID ALLERGEN IN PLANTS
WO2004082368A2 (en) * 2003-03-18 2004-09-30 Rutgers, The State University Improved plant transformation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008161A1 (en) * 1989-01-12 1990-07-26 The Blood Center Of Southeastern Wisconsin Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses
WO1992006708A1 (en) * 1990-10-15 1992-04-30 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
WO1994020135A1 (en) * 1993-03-04 1994-09-15 Edible Vaccines Inc. Vaccines expressed in plants
WO1995008347A1 (en) * 1993-09-21 1995-03-30 London Health Association Methods and products for controlling immune responses in mammals
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
WO1995028424A1 (en) * 1994-04-14 1995-10-26 Immulogic Pharmaceutical Corporation Pharmaceutical peptide formulations for treatment of dust mite allergy
WO1995030435A2 (en) * 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008161A1 (en) * 1989-01-12 1990-07-26 The Blood Center Of Southeastern Wisconsin Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses
WO1992006708A1 (en) * 1990-10-15 1992-04-30 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
WO1994020135A1 (en) * 1993-03-04 1994-09-15 Edible Vaccines Inc. Vaccines expressed in plants
WO1995008347A1 (en) * 1993-09-21 1995-03-30 London Health Association Methods and products for controlling immune responses in mammals
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
WO1995028424A1 (en) * 1994-04-14 1995-10-26 Immulogic Pharmaceutical Corporation Pharmaceutical peptide formulations for treatment of dust mite allergy
WO1995030435A2 (en) * 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRINER, T.J., ET AL.: "PERIPHERAL T-CELL TOLERANCE INDUCED IN NAIVE AND PRIMED MICE BY SUBCUTANEOUS INJECTION OF PEPTIDES FROM MAJOR CAT ALLERGEN FEL d1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 90, August 1993 (1993-08-01), pages 7608 - 7612, XP002056822 *
GRIFFITH I J ET AL: "EXPRESSION AND GENOMIC STRUCTURE OF THE GENES ENCODING FDI, THE MAJOR ALLERGEN FROM THE DOMESTIC CAT", GENE, vol. 113, 1992, pages 263 - 268, XP002033869 *
MA, S.-W., ET AL.: "TRANSGENIC PLANTS EXPRESSING AUTOANTIGENS FED TO MICE TO INDUCE ORAL IMMUNE TOLERANCE", NATURE MEDICINE, vol. 3, no. 7, July 1997 (1997-07-01), pages 793 - 796, XP002056824 *
MASON H S ET AL: "TRANSGENIC PLANTS AS VACCINE PRODUCTION SYSTEMS", TRENDS IN BIOTECHNOLOGY, vol. 13, no. 9, September 1995 (1995-09-01), pages 388 - 392, XP002024035 *
MUELLER U ET AL: "SUCCESFUL IMMUNOTHERAPY WITH T-CELL EPITOPES OF BEE VENOM PHOSPHOLIPASE A2 (PLA) IN PATIENTS WITH BEE VENOM (BV) ALLERGY", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 97, no. 1, PART 03, January 1996 (1996-01-01), pages 426, XP002035179 *
SAYEGH, M.H., ET AL .: "INDUCTION OF IMMUNITY AND ORAL TOLERANCE WITH POLYMORPHIC CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES IN THE RAT", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, August 1992 (1992-08-01), pages 7762 - 7766, XP002056823 *

Also Published As

Publication number Publication date
CA2263730A1 (en) 1998-02-19
WO1998006861A2 (en) 1998-02-19
AU3825497A (en) 1998-03-06
EP0939826A2 (en) 1999-09-08

Similar Documents

Publication Publication Date Title
AU2001268645A1 (en) Insoluble protein particles
MX9600483A (en) Flavouring composition and process.
AU2002347442A1 (en) Perfuming or flavouring microcapsules comprising a fireproofing agent
WO2002047612A3 (en) Dietary supplement compositions
WO2001072262A3 (en) New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
WO2001066136A3 (en) Microbial delivery system
HK1042051A1 (en) Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
CA2262652A1 (en) Anti-stress drugs and functional foods having anti-stress effects
AU5397699A (en) Pasteurized or ultra-pasteurized complete nutritional compositions and products
WO2003084467A3 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
WO1999008708A3 (en) Method and food product for increasing muscle protein and reducing fat in animals
AU4073901A (en) Novel pharmaceutical or dietetic mushroom-based compositions
WO1998006861A3 (en) Delivery of tolerogenic antigens via edible plants or plant-derived products
WO2002056708A3 (en) Preparation for improved dietary utilisation
EP0747039A3 (en) Antisolar and antierythema composition based on natural products
WO1998037775A3 (en) Gelled emulsion products containing chitosan
AU1275401A (en) Fibrous-liponutritional complexes and compositions containing them
AU5496196A (en) Edible lactose-containing compositions and their use in the manufacture of food products
CA2072658A1 (en) Use of honey as vaccine
BG101506A (en) LIQUEUR, FLAVORED WITH SMOKED EGG SHEARS
WO2001017536A3 (en) Novel autogenous vaccines used to obtain an immune tolerance
WO2004095951A3 (en) Food products comprising natural extracts or fragrances of plants together with aminoacids and use thereof for fighting smoke addiction
BR0005196A (en) Creamy vegetable product, normal or light
EP1256283A3 (en) Phytopharmaceutical food products
XuShiying Chemical Modification of Food Proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2263730

Country of ref document: CA

Ref country code: CA

Ref document number: 2263730

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09242296

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997935275

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998509808

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997935275

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997935275

Country of ref document: EP